The Cardiovascular Disorders Market Outlook to 2012
By Revati Nehru
Executive Summary 14
Patient potential 14
Global market analysis 15
Pipeline analysis 16
Competitive landscape 17
Chapter 1 Epidemiology of Cardiovascular disorders 20
Summary 20
Introduction 21
Cardiovascular Risk Factors 22
Hypertension 25
Overview 25
Diagnosis, treatment and management 26
Epidemiology 28
Forecast epidemiology 30
Dyslipidemia 31
Overview 31
Diagnosis, treatment and management 33
Epidemiology 35
Forecast epidemiology 36
Diabetes 37
Overview 37
Diagnosis, treatment and management 38
Epidemiology 40
Forecast epidemiology 41
Cardiovascular disease 42
Overview 42
Epidemiology 44
Acute thrombotic events 45
Acute coronary syndromes 45
Venous thromboembolism 48
Stroke 50
Cardiovascular procedures 53
Chapter 2 Global market analysis 58
Summary 58
Introduction 59
Market analysis by country 59
Licensing trends 60
Market analysis by drug class 62
Leading brands dynamics 64
Key events in the cardiovascular market 66
Use of ACE inhibitors by pregnant women linked to associated birth defects risks
66
Arrival of generic competition to key brands 67
Positive clinical trials further boost sales generation for major brands Diovan
and Lipitor 67
Anti-hypertensives 68
Market analysis by drug class 68
Leading brands in the Anti-hypertensives market 70
ACE Inhibitors (ACEIs) 72
Market dynamics 74
Key brands analysis 75
Beta Blockers 80
Market dynamics 82
Diuretics 83
Market dynamics 85
Key brands analysis 85
Calcium Channel Blockers (CCBs) 86
Market dynamics 88
Key brands analysis 89
Angiotensin Receptor Blockers (ARBs) 90
Market dynamics 93
Key brands analysis 94
Sales forecasts to 2012 for Anti Hypertensives 100
Anti-dyslipidemics 102
Market analysis by drug class 102
Leading brands in the Anti-dyslipidemics market 105
Market analysis by drug class 106
Statins 106
Fibrates 113
Non-statin products 113
Other anti-dyslipidemics 115
Sales forecasts to 2012 for Anti dyslipidemics 115
Anti-Thrombotics 116
Market analysis by drug class 116
Leading brand dynamics 119
Anti-platelets 121
Market dynamics 124
Key brands analysis 125
Heparins 128
Market dynamics 130
Key brands analysis 130
Vit K antagonists 134
Fibrinolytics 136
Sales forecasts to 2012 for Anti thrombotics 137
Cardiac Therapies 138
Market analysis by drug class 138
Leading brands of Cardiac Therapies 142
Other cardiac therapies 142
Nitrites and nitrates 144
Leading-brand dynamics 144
Anti-arrhythmics 145
Sales forecasts to 2012 for Cardiac Therapies 2007-12 146
Total CVD market sales forecasts to 2012 147
Chapter 3 Pipeline analysis 150
Summary 150
Introduction 151
Key trends in cardiovascular R&D 151
Combination drugs 152
New class of drugs 153
New mechanism of action 153
New drug delivery formulations 153
The pipeline for cardiovascular disorders 154
Leading drugs in development 156
Profiles of key pipeline products 157
Phase II compounds 157
ARC 1779 157
KB 2115 158
Phase III compounds 160
Cleviprex (clevidipine) 160
Stedicor (azimilide) 162
BAY-597939 (rivaroxaban) 163
Drugs pending approval 165
Thelin (sitaxsentan) 165
Simcor (niacin and simvastatin) 167
Recently marketed drugs 169
Azor (amlodipine/olmesartan) 169
Tekturna/Rasilez (aliskiren) 171
Exforge (amlodipine/valsartan) 173
Ranexa (ranolazine) 174
Chapter 4 Competitive landscape 178
Summary 178
Company market shares 179
Pfizer 183
Overview 183
Sales focus by drug class 183
Marketed product portfolio 184
R&D pipeline analysis 185
Strategic and growth analysis 186
Drivers of growth 186
Resistors of growth 186
Merck 187
Overview 187
Sales focus by drug class 187
Marketed product portfolio 188
R&D pipeline analysis 189
Strategic and growth analysis 190
Drivers of growth 190
Resistors of growth 190
Novartis 191
Overview 191
Sales focus by drug class 191
Marketed product portfolio 192
R&D compounds 193
Strategic and growth analysis 194
Drivers of growth 194
Resistors of growth 194
Sanofi Aventis 195
Overview 195
Sales focus by drug class 195
Marketed product portfolio 196
R&D pipeline analysis 197
Strategic and growth analysis 198
Drivers of growth 198
Resistors of growth 198
AstraZeneca 199
Overview 199
Sales focus by drug class 199
Marketed product portfolio 200
R&D pipeline analysis 201
Strategic and growth analysis 201
Drivers of growth 201
Resistors of growth 202
Bristol-Myers Squibb 203
Overview 203
Sales focus by drug class 203
Marketed product portfolio 204
R&D pipeline analysis 205
Strategic and growth analysis 205
Drivers of growth 205
Resistors of growth 206
Daiichi Sankyo 207
Overview 207
Sales focus by drug class 207
Marketed product portfolio 208
R&D pipeline analysis 209
Strategic and growth analysis 210
Drivers of growth 210
Resistors of growth 210
Servier 211
Overview 211
Sales focus by drug class 211
Marketed product portfolio 212
R&D pipeline analysis 213
Strategic and growth analysis 213
Drivers of growth 213
Resistors of growth 213
Glaxo SmithKline 214
Overview 214
Sales focus by drug class 214
Marketed product portfolio 215
R&D pipeline analysis 216
Strategic and growth analysis 217
Drivers of growth 217
Resistors of growth 217
Chapter 5 Appendix 220
ATC codes used in analysis 220
Licensing status as per IMS Health 220
Original brand 220
Other brand 221
Licensed brand 221
Not-coded product 221
Unbranded/ generic product 221
Diagnosis profile analysis 222
Index 223
List of Figures
Figure 1.1: Relationship between Cardiovascular Risk Factors and Diseases 23
Figure 1.2: Typical treatment patterns in the treatment of hypertension 28
Figure 1.3: Typical treatment patterns in the treatment of dyslipidemia 34
Figure 1.4: Typical treatment patterns in the treatment of diabetes 39
Figure 1.5: Typical treatment patterns in the treatment of acute thrombotic
events 52
Figure 2.6: Global cardiovascular market share by geography, 2007 60
Figure 2.7: Sales of types of cardiovascular brands, 2006-07 61
Figure 2.8: Competitive dynamics of the global CVD market by drug class, 2007 63
Figure 2.9: Forecast dynamics of the leading 10 cardiovascular brands, 2006-07
66
Figure 2.10: Competitive dynamics in the global anti-hypertensives market by
drug class, 2006–07 69
Figure 2.11: Market movement for anti-hypertensive brands, 2006 71
Figure 2.12: Diagnosis profile of ACE inhibitor sales, 2006 73
Figure 2.13: Diagnosis profile of Beta Blockers, 2006 81
Figure 2.14: Diagnosis profile of Calcium channel blockers, 2006 87
Figure 2.15: Diagnosis profile of ARBs, 2006 92
Figure 2.16: Diagnosis profile of Anti-dyslipidemics, 2006 104
Figure 2.17: Competitive dynamics in the global anti-thrombotics market by
class, 2006–07 119
Figure 2.18: Market movement for anti-thrombotic brands, 2006 121
Figure 2.19: Diagnosis profile of anti-platelets, 2006 123
Figure 2.20: Diagnosis profile of Heparins, 2006 129
Figure 2.21: Diagnosis profile of cardiac therapies, 2006 140
Figure 2.22: Competitive dynamics in the global cardiac therapies market by
class, 2006–07 141
Figure 3.23: Prevailing R&D approaches for cardiovascular diseases, 2006 152
Figure 3.24: The CVD pipeline by indication and stage of development, 2006 155
Figure 3.25: Leading recently launched and late-stage cardiovascular products,
2007 156
Figure 4.26: Competitive dynamics of the leading players in the global
cardiovascular market, 2007 182
Figure 4.27: Pfizer’s franchise sales by drug class, 2006 183
Figure 4.28: Merck’s franchise sales by drug class, 2006 187
Figure 4.29: Novartis’ franchise sales by drug class, 2006 191
Figure 4.30: Sanofi Aventis’ franchise sales by drug class, 2006 195
Figure 4.31: AstraZeneca’s franchise sales by drug class, 2006 199
Figure 4.32: BMS’ franchise sales by drug class, 2006 203
Figure 4.33: Daiichi’s franchise sales by drug class, 2006 207
Figure 4.34: Servier’s franchise sales by drug class, 2006 211
Figure 4.35: GSK’s franchise sales by drug class, 2006 214
List of Tables
Table 1.1: Estimated prevalence of CVD across the seven major pharmaceutical
markets, 2006 24
Table 1.2: Proposed revision definition of hypertension, 2005 26
Table 1.3: Estimated prevalence of hypertension in across seven major markets,
2006 29
Table 1.4: Forecast epidemiology of hypertension across the seven major markets,
2006-12 30
Table 1.5: Clinical guidelines for adult patients at borderline and high risk of
cardiovascular
disease by serum levels of lipids 33
Table 1.6: Estimated prevalence of dyslipidemia across seven major markets, 2006
35
Table 1.7: Forecast epidemiology of dyslipidemia across the seven major markets,
2006-12 36
Table 1.8: Various pharmacological therapies for the treatment and management of
diabetes 39
Table 1.9: Estimated prevalence of diabetes in the seven major markets, 2006 40
Table 1.10: Forecast epidemiology of diabetes across the seven major markets,
2006-12 41
Table 1.11: Estimated prevalence of major cardiovascular diseases in the seven
major markets,2006 44
Table 1.12: Estimated incidence of ACS in the seven major markets, 2006 47
Table 1.13: Estimated incidence of VTE in the seven major markets, 2006 49
Table 1.14: Prevalence of stroke in the seven major markets, 2006 51
Table 1.15: Estimated incidence of cardiovascular procedures in the seven major
markets, 2006 54
Table 2.16: Breakdown of the global CVD market by drug class, 2003-07 62
Table 2.17: Leading brands in the global cardiovascular market, 2006–07 64
Table 2.18: Breakdown of the global anti-hypertensive market by drug class,
2003-07 68
Table 2.19: Leading anti-hypertensive brands, 2006–07 70
Table 2.20: Leading ACE inhibitor brands, 2006–07 74
Table 2.21: Leading Beta blocker brands, 2006–07 82
Table 2.22: Leading diuretics brands, 2006–07 85
Table 2.23: Leading CCBs brands in the global CVD market, 2006–07 88
Table 2.24: Leading ARBs brands in the global CVD market, 2006–07 93
Table 2.25: Anti-hypertensives sales forecast for ARBs, Beta-blockers & CCBs,
2007-12 100
Table 2.26: Anti-hypertensives sales forecast for ACE inhibitors, Diuretics &
Pipeline products,2007-12 101
Table 2.27: Breakdown of the global anti-dyslipidemic market by drug class,
2003-07 103
Table 2.28: Leading anti-dyslipidemia products in the global CVD market, 2006–07
105
Table 2.29: Anti-dyslipidemics sales forecasts, 2007-12 116
Table 2.30: Breakdown of the global anti-thrombotics market by drug class,
2003-07 117
Table 2.31: Leading anti-thrombotics products in the global CVD market, 2006–07
120
Table 2.32: Leading anti-platelet brands in the global CVD market, 2006–07 124
Table 2.33: Leading heparin brands in the global CVD market, 2006–07 130
Table 2.34: Anti-thrombotics sales forecasts, 2007-12 137
Table 2.35: Breakdown of the global anti-thrombotics market by drug class,
2003-07 139
Table 2.36: Leading cardiac therapy products in the global CVD market, 2006–07
142
Table 2.37: Cardiac therapies’ sales forecasts, 2007-12 146
Table 2.38: Cardiovacular market sales forecasts by drug class, 2006-12 ($m) 147
Table 4.39: Leading players in the global cardiovascular disorders market,
2006-07 179
Table 4.40: Pfizer’s CVD product portfolio, 2005-06 184
Table 4.41: Pfizer’s cardiovascular product pipeline, 2006 185
Table 4.42: Merck’s CVD product portfolio, 2005-06 188
Table 4.43: Merck’s cardiovascular R&D product pipeline, 2006 189
Table 4.44: Novartis’ CVD product portfolio, 2005-06 192
Table 4.45: Novartis’ cardiovascular R&D product pipeline, 2006 193
Table 4.46: Sanofi Aventis’ CVD product portfolio, 2005-06 196
Table 4.47: Sanofi Aventis’ cardiovascular R&D product pipeline, 2006 197
Table 4.48: AstraZeneca’s CVD product portfolio, 2005-06 200
Table 4.49: AstraZeneca’s cardiovascular R&D product pipeline, 2006 201
Table 4.50: BMS’s CVD product portfolio, 2005-06 204
Table 4.51: BMS’ cardiovascular R&D product pipeline, 2006 205
Table 4.52: Daiichi’s CVD product portfolio, 2005-06 208
Table 4.53: Daichii’s cardiovascular R&D product pipeline, 2006 209
Table 4.54: Servier’s CVD product portfolio, 2005-06 212
Table 4.55: GSK’s CVD product portfolio, 2005-06 215
Table 4.56: GSK’s cardiovascular R&D product pipeline, 2006 216